| Name | Miglustat |
| Synonyms | NB-DNJ OGT-918 Mg gross SC-48334 Miglustat N-BUTYLDEOXYNOJIRIMYCIN N-BUTYL-1-DEOXYNOJIRIMYCIN 1,5-(Butylimino)-1,5-dideoxy-D-glucitol 1-Butyl-2α-(hydroxymethyl)piperidine-3β,4α,5β-triol (2R)-1-Butyl-2α-(hydroxymethyl)piperidine-3β,4α,5β-triol |
| CAS | 72599-27-0 |
| EINECS | 207-526-1 |
| InChIKey | UQRORFVVSGFNRO-UTINFBMNSA-N |
| Molecular Formula | C10H21NO4 |
| Molar Mass | 219.28 |
| Density | 1.234 |
| Melting Point | 126-127℃ |
| Boling Point | 394.7±42.0 °C(Predicted) |
| Specific Rotation(α) | D25 -15.9° (c = 0.77 in water) |
| Water Solubility | Soluble in water at 10mg/ml |
| Solubility | Soluble in water at 10mg/ml |
| Appearance | White powder |
| Color | White |
| pKa | 13.72±0.70(Predicted) |
| Storage Condition | 2-8°C |
| MDL | MFCD00272581 |
| WGK Germany | 3 |
| RTECS | TN4350150 |
| application | meglut is a drug developed by Oxford GlycoSciences company and listed by Actelion company, mainly used to treat type I Gaucher disease (GD1). N alkylated derivatives of 1-deoxynojirimycin have received more and more attention in the field of medicine. Gaucher's disease (Gauchers disease) is a hereditary glycolipid excess disease. Due to the lack of specific β-glucosidase, the glucosylceramide in the body cannot be degraded smoothly. The main clinical symptoms include bone pain and anemia. Megrut has a strong inhibitory effect on glucosylceramide synthase. It was approved to be marketed in Europe in 2003 for the treatment of Gaucher's disease. |
| Preparation | According to the mechanism of Mannich reaction (Mannich Reaction), N-propyl deoxynojirimycin was synthesized from 1-deoxynojirimycin as the starting material. The synthesis reaction formula of Megrut is as follows: |
| Biological activity | Miglustat (N-Butyldeoxynojirimycin) is a glucose ceramide synthetase inhibitor that can act on type I Gaucher's disease. |